Q2 2026 Biontech SE Earnings Call Transcript

Aug 4, 2026 / 12:00 PM GMT

Release Date Price: €81 (-0.74%)

Transcript

Key Points

Positve

BioNTech SE (BNTX) reported encouraging global Phase II data for its next-generation IO backbone, Pumetamic, in first-line non-small cell lung cancer, showing robust clinical activity across all PD-L1 expression levels, including a 47.6% confirmed objective response rate in PD-L1-negative patients.
The company is advancing a broad late-stage oncology pipeline with more than 17 late-stage and pivotal trials planned through 2030, including four registrational programs for Pumetamic in lung cancer and a Phase III trial for its B7H3 ADC (LVD) in metastatic castration-resistant prostate cancer.
BioNTech SE (BNTX) maintains a strong financial position with $16.6 billion in cash equivalents and security investments, enabling sustained investment in its pipeline and the execution of its up to $1 billion share repurchase program, with $152 million already repurchased.
The company is executing a disciplined capital allocation strategy, including a revised R&D expense guidance of $2.0-$2.3 billion, reflecting cost savings from portfolio prioritization and favorable cost-sharing effects from collaboration partners.
BioNTech SE (BNTX) expects multiple key data readouts in the second half of 2026, including the first interim analysis for Gotistobart in squamous non-small cell lung cancer, the Phase III interim analysis for BNT113 in head and neck cancer, and the primary analysis for TPAM in breast cancer.
The company's combination therapy strategy is gaining momentum, with plans to present the first clinical data for Pumetamic in combination with its B7H3 ADC (LVD) in lung cancer, which could de-risk and inform upcoming registrational combination trials.

Negative

BioNTech SE (BNTX) revised its full-year 2026 revenue guidance downward to $1.6-$1.9 billion, primarily due to softer-than-anticipated global COVID-19 vaccine demand and the European Medicines Agency's recommendation allowing the use of previous-year vaccine formulas, leading to significantly reduced sales in Germany.
Second-quarter 2026 revenues declined sharply to $106 million from $261 million in the prior year quarter, reflecting lower demand for its COVID-19 vaccine in the U.S. and the absence of a one-time compensation payment from Pfizer.
The company delayed the expected timing for the Phase III Pumetamic trial in triple-negative breast cancer in China and the Phase II Gotistobart trial in second-line castration-resistant prostate cancer, both now expected in 2027, due to slower-than-expected event accrual.
SG&A expenses increased to $198 million in Q2 2026 from $137 million in the prior year quarter, driven by global initiatives to scale processes and ERP infrastructure, as well as ongoing pre-launch activities for late-stage programs.
The company is incurring significant impairment charges and employee-related costs related to its manufacturing footprint consolidation, which weigh on near-term results, although management frames these as deliberate investments in future operational efficiency.
The timing of micron-related revenues from an out-licensed R&D program is no longer expected in 2026, contributing to the revenue guidance reduction, with approximately 80% of the adjustment attributed to COVID-related factors.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

BNTX.OQ - BioNTech SE
Q2 2026 Biontech SE Earnings Call
Aug 04, 2026 / 12:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Thank you, operator. Good morning and good afternoon.

Thank you for joining BioNTech's second quarter 2026 earnings call.

As a reminder, the slides we will be using during this call and the corresponding press release can be found in the Investors section of our website.

On the next slide, you will see our forward-looking statements disclaimer.

Additional information about these statements and other risks are described in our filings with the U.S. Securities and Exchange Commission, or SEC.

Forward-looking statements on this call are subject to significant risks and uncertainties and speak only as of the date of this conference call.

We undertake no obligation to update or revise any of these

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.